Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to -$3.5 million.

  • Oncology Institute's Cash from Financing Activities rose 446213.99% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 17226.91%. This contributed to the annual value of -$3.5 million for FY2024, which is 4899.96% up from last year.
  • Latest data reveals that Oncology Institute reported Cash from Financing Activities of -$3.5 million as of FY2024, which was up 4899.96% from -$6.8 million recorded in FY2023.
  • In the past 5 years, Oncology Institute's Cash from Financing Activities ranged from a high of $154.0 million in FY2021 and a low of -$6.8 million during FY2023
  • Its 5-year average for Cash from Financing Activities is $49.6 million, with a median of $11.9 million in 2020.
  • As far as peak fluctuations go, Oncology Institute's Cash from Financing Activities soared by 119550.81% in 2021, and later plummeted by 10742.58% in 2023.
  • Annual analysis of 5 years shows Oncology Institute's Cash from Financing Activities stood at $11.9 million in 2020, then soared by 1195.51% to $154.0 million in 2021, then tumbled by 40.13% to $92.2 million in 2022, then crashed by 107.43% to -$6.8 million in 2023, then skyrocketed by 49.0% to -$3.5 million in 2024.
  • Its Cash from Financing Activities stands at -$3.5 million for FY2024, versus -$6.8 million for FY2023 and $92.2 million for FY2022.